Ann D. Rhoads - 28 Jan 2026 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Reporting relationship: Director
Issuer ticker: RPTX
Reported as of: 28 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jan 2026, 20:30:10 UTC
Prior SEC filing: 23 Jan 2026
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Steve Forte, Attorney-in-Fact

Key filing fact

Ann D. Rhoads filed Form 4 for Repare Therapeutics Inc. (RPTX) on 28 Jan 2026.

Key facts

This page summarizes Ann D. Rhoads's Form 4 filing for Repare Therapeutics Inc. (RPTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jan 2026, 20:30.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001250252 Primary reporting owner

RHOADS ANN D

Relationship: Director
Address: C/O REPARE THERAPEUTICS INC., 7171 FREDERICK-BANTING, BLDG 2, SUITE 27, ST-LAURENT, QUEBEC, CANADA
Signature: /s/ Steve Forte, Attorney-in-Fact
Signature date: 28 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPTX transaction

Common Shares

Disposed to Issuer

Transaction value
Shares: -4,000
Change %: -100%
Price
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Ann D. Rhoads is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.

Footnote F2

Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.